Arch On­col­o­gy thinks it can stand out in the red-hot CD47 field, and it's tak­ing $105M in new cash to prove it

In the past few years, a spate of com­pa­nies have jumped in­to the search for a can­cer ther­a­py that blocks CD47’s “don’t eat me” sig­nal. A group of crossover in­vestors is now bet­ting $105 mil­lion on Arch On­col­o­gy’s play — but CEO Lau­rence Blum­berg says he’s not plan­ning on go­ing pub­lic just yet.

The funds will back Arch’s Phase I/II can­di­date AO-176, which is be­ing test­ed both on its own and in com­bi­na­tion stud­ies in pa­tients with sol­id tu­mors and hema­to­log­ic ma­lig­nan­cies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER